JPIAMR: Network proposal call; BARDA: DRIVe Accelerator call

Dear All: I trust you are now home after ECCMID in Madrid … it was an excellent meeting. Two new funding opportunities have recently crossed my radar: brief summaries and one key link for each are here with some further details below my signature. 

  • EU JPIAMR funding call: As part of its Virtual Research Institute (VRI) initiative, JPIAMR wants to fund as many as 22 collaborative research networks.
  • US BARDA Funding Opportunity Announcement: Building on the job opportunities recently announced for its DRIVe initiative, BARDA is creating an accelerator network providing technical and business development support services to programs funded by DRIVe.

This is great to see happening! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

JPIAMR call for network proposals: https://www.jpiamr.eu/pre-announcement-8th-call-building-the-foundation-of-the-jpiamr-vri/

  • JPIAMR seeks to encourage research alignment via establishing a Virtual Research Institute in AMR – a global network connecting research performing organisations, including institutes, centres, and infrastructures.
  • In partnership with ten member countries; Canada, Egypt, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom, JPIAMR is launching the 8th joint call for transnational Networks. The total budget of the call is approximately 1.1 million Euro. This Network Call “Building the Foundation of the JPIAMR Virtual Research Institute” aims to identify research community needs and develop ideas to form the foundation for the JPIAMR-VRI
  • Up to 22 Networks will be funded with up to €50 000 each coordinator to connect experts from research performing organisations and establish expertise clusters in the AMR community.
  • The formation of larger, multi-coordinator Networks is possible according to national rules.
  • Deadline for proposals is 4 July 2018.

BARDA DRIVEe Accelerator Network: Funding Opportunity Announcement: https://www.grants.gov/web/grants/view-opportunity.html?oppId=303785

  • BARDA’s newest Division of Research, Innovation and Ventures (DRIVe), will stimulate public-private partnership collaborations that spur innovation and investment in health security products and technologies to repopulate the development pipeline and stimulate the public good of the nation. 
  • A key component of this is the DRIVe Accelerator Network, where accelerators work together to identify promising, innovation and then provide wraparound technical and business development support services to programs funded by DRIVe. 
  • DRIVe Accelerator Network support teams will bring together a network of multiple accelerators, building on their individual strengths and unleash them to work directly with product developers funded by DRIVe.  
  • Product development candidates that graduate from DRIVe with support of the DRIVe Accelerator Network will be better positioned for advanced R&D investment, clinical development, and commercialization. 
  • The deadline for proposals is 17 May 2018.

Upcoming meetings of interest to the AMR community:

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top